Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-05-31

FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental application for Sabril (vigabatrin) from Lundbeck Pharmaceuticals LLC. The action completes an approved supplemental NDA for vigabat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SABRIL (VIGABATRIN)
  • Vigabatrin (Vigabatrin)

Snippet

SUPPL AP for SABRIL (VIGABATRIN)